To seek candidates for targeted therapy that are synthetically lethal to loss of SMARCA4 in NSCLC cells, we conducted a whole-genome siRNA library screen in a cell line belonging to a panel of NSCLC-derived cell lines that has been extensively characterized21. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.